Lv2
191 积分 2021-11-16 加入
PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression
10小时前
已完结
Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase 2b KEYNOTE-942 Study
7天前
已完结
Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301)
12天前
已完结
Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase 2b KEYNOTE-942 Study
13天前
已关闭
Targeting intratumoral heterogeneity in pancreatic cancer with sequential TIL infusions
21天前
已完结
Targeting intratumoral heterogeneity in pancreatic cancer with sequential TIL infusions
21天前
已关闭
Suppression of cytokine release syndrome during CAR-T-cell therapy via a subcutaneously injected interleukin-6-adsorbing hydrogel
21天前
已完结
Pan-cancer spatial atlas of tertiary lymphoid structures
25天前
已完结
Phase II study of apatinib combined with temozolomide in patients with advanced melanoma after failure of immunotherapy
25天前
已完结
Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination
25天前
已完结
皖公网安备34019202002308
